Immunic
IMUX
55 hedge funds and large institutions have $35M invested in Immunic in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 14 closing their positions.
1,050% more call options, than puts
Call options by funds: $161K | Put options by funds: $14K
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0.74% more ownership
Funds ownership: 4.49% → 5.24% (+0.74%)
14% less funds holding
Funds holding: 64 → 55 (-9)
21% less capital invested
Capital invested by funds: $44.1M → $35M (-$9.11M)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$6.6M |
| 2 |
Morgan Stanley
New York
|
+$2.81M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.54M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.07M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$767K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.15M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.04M |
| 3 |
6CM
683 Capital Management
New York
|
-$769K |
| 4 |
Renaissance Technologies
New York
|
-$493K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$471K |
IMUX Hedge Fund Activity: Q2 2025 in Review
55 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2025, worth a combined $35M — down 21% from $44.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IMUX and 5 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Aberdeen Group, adding an estimated $6.6M. The largest seller was BVF Inc, cutting an estimated $1.15M.
- 55 institutional investors held Immunic (IMUX) as of Q2 2025, down from 64 in Q1 2025.
- Funds reported $35M of Immunic stock for Q2 2025, down 21% quarter-over-quarter.
- 5 funds opened new Immunic positions in Q2 2025 and 14 closed out, a net change of -9 holders.
- The largest Immunic buyer in Q2 2025 was Aberdeen Group, an estimated $6.6M added.
- The largest Immunic seller in Q2 2025 was BVF Inc, an estimated $1.15M sold.
Based on aggregated 13F filings for Q2 2025.